Eliem Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
CLYM$11.74+6.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Operating expenses: | ||
| Research and development | $15,411 | $26,214 |
| General and administrative | 24,864 | 18,921 |
| Total operating expenses | 40,275 | 45,135 |
| Loss from operations | (40,275) | (45,135) |
| Other income (expense): | ||
| Foreign currency gain (loss) | 536 | (1,484) |
| Interest income, net | 4,620 | 1,375 |
| Total other income (expense) | 5,156 | (109) |
| Net loss | $(35,119) | $(45,244) |
| Net loss per share, basic and diluted | $(1.30) | $(1.72) |
| Weighted-average number of shares used to compute net loss per share, basic and diluted | 26,987,122 | 26,311,554 |
| Comprehensive loss: | ||
| Net loss | $(35,119) | $(45,244) |
| Other comprehensive income (loss): | ||
| Unrealized gain (loss) on investments, net of tax of $0 | 356 | (235) |
| Comprehensive loss | $(34,763) | $(45,479) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.